1-(2-(4-aminophenyl)ethyl)-4-(3-trifluoromethylphenyl)piperazine has been researched along with cilostamide in 2 studies
| Studies (1-(2-(4-aminophenyl)ethyl)-4-(3-trifluoromethylphenyl)piperazine) | Trials (1-(2-(4-aminophenyl)ethyl)-4-(3-trifluoromethylphenyl)piperazine) | Recent Studies (post-2010) (1-(2-(4-aminophenyl)ethyl)-4-(3-trifluoromethylphenyl)piperazine) | Studies (cilostamide) | Trials (cilostamide) | Recent Studies (post-2010) (cilostamide) |
|---|---|---|---|---|---|
| 53 | 0 | 15 | 192 | 0 | 67 |
| Protein | Taxonomy | 1-(2-(4-aminophenyl)ethyl)-4-(3-trifluoromethylphenyl)piperazine (IC50) | cilostamide (IC50) |
|---|---|---|---|
| cGMP-dependent 3',5'-cyclic phosphodiesterase | Homo sapiens (human) | 0.005 | |
| High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8A | Homo sapiens (human) | 0.005 | |
| cGMP-specific 3',5'-cyclic phosphodiesterase | Homo sapiens (human) | 3.5775 | |
| Platelet-activating factor receptor | Homo sapiens (human) | 3.687 | |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4D | Homo sapiens (human) | 0.005 | |
| cGMP-inhibited 3',5'-cyclic phosphodiesterase B | Homo sapiens (human) | 0.0502 | |
| cGMP-inhibited 3',5'-cyclic phosphodiesterase A | Homo sapiens (human) | 0.0362 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Austin, CP; Fidock, DA; Hayton, K; Huang, R; Inglese, J; Jiang, H; Johnson, RL; Su, XZ; Wellems, TE; Wichterman, J; Yuan, J | 1 |
2 other study(ies) available for 1-(2-(4-aminophenyl)ethyl)-4-(3-trifluoromethylphenyl)piperazine and cilostamide
| Article | Year |
|---|---|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
Topics: Animals; Antimalarials; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chromosome Mapping; Crosses, Genetic; Dihydroergotamine; Drug Design; Drug Resistance; Humans; Inhibitory Concentration 50; Mutation; Plasmodium falciparum; Quantitative Trait Loci; Transfection | 2009 |